MBC

eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual Meeting

Retrieved on: 
Wednesday, November 15, 2023
Therapy, Annual general meeting, STRI Group, Clinical trial, Patient, MBC, Trial of the century, Cancer

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium 2023 Annual Meeting, taking place from December 5 – 9, 2023 in San Antonio, Texas.

Key Points: 
  • SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Cancer Symposium 2023 Annual Meeting, taking place from December 5 – 9, 2023 in San Antonio, Texas.
  • eFFECTOR plans to discuss the results of the clinical trial and provide further updates on zotatifin development at the conference.
  • Presentation details can be found below.
  • Presenter: Ezra Rosen, M.D., Ph.D., Medical Oncologist & Early Drug Development Specialist, Memorial Sloan Kettering Cancer Center
    At the time of presentation, eFFECTOR’s poster will be made available on the “Publications & Presentations” page of the “Science” section of its website.

Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023

Retrieved on: 
Friday, December 8, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, DSM-IV codes, Vomiting, Woman, Safety, CDK, Potassium, Therapy, Letrozole, Progression-free survival, Back pain, Fulvestrant, Abdominal pain, Doctor of Science, Headache, Risk, Liver, Disease, Cholesterol, PIK3CA, Constipation, Fatigue, Indigestion, Anastrozole, Patient, Multimedia, PFS, Metastasis, MD Anderson Cancer Center, ESR1, FDA, MBC, Neoplasm, Creatinine, Standard of care, Diarrhea, MD, Nausea, Cancer, Trial of the century, Death, Exemestane, Menarini, Anemia, SOC, TP53, Knowledge, Arthralgia, HIV disease progression rates, Triglyceride, Medical imaging, Pharmaceutical industry

This data is being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.

Key Points: 
  • This data is being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • ESR1 mutations are present in up to 40% of ER+, HER2- advanced or mBC.
  • “At Menarini Stemline our goal is to provide transformational treatments to help extend and improve the lives of people living with cancer.
  • See here for details of the Menarini Group/Stemline Therapeutics' full range of presentations at SABCS 2023.

MasterBrand, Inc. to Locate Corporate Headquarters Near Cleveland

Retrieved on: 
Thursday, December 7, 2023
Other Manufacturing, Commercial Building & Real Estate, Construction & Property, Human Resources, Professional Services, Public Policy, Government, Interior Design, Manufacturing, State, Local, Residential Building & Real Estate, NYSE, City, Investment, MBC, Knowledge, Transport, Management

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), North America’s largest manufacturer of residential cabinets, has announced plans to locate its corporate headquarters in Beachwood, Ohio.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), North America’s largest manufacturer of residential cabinets, has announced plans to locate its corporate headquarters in Beachwood, Ohio.
  • “We look forward to opening our headquarters here soon and welcoming our customers and partners from across North America.”
    With more than 20 manufacturing facilities and offices across the country, MasterBrand considered several options for locating its headquarters.
  • “I have a long history with and knowledge of the excellence of MasterBrand’s residential cabinets,” said Beachwood City Mayor Justin Berns.
  • Additionally, the lower cost of doing business and strong investments in innovation make it a good choice for manufacturers and corporate headquarters alike.

Greenspace Health & the Community Behavioral Health Association of Maryland Driving Significant Improvements in Behavioral Health Services Across the State

Retrieved on: 
Tuesday, December 5, 2023
Hospitals, Health, Mental Health, Other Health, PHQ-9, MBC, State, Depression, GAD-7, Anxiety, Coordination, Nursing, Greenspace

“There is growing momentum for MBC in Maryland being driven by many clinical and system leaders prioritizing MBC as a foundational component of evidence based service delivery, as they recognize its importance in ensuring high-quality care.

Key Points: 
  • “There is growing momentum for MBC in Maryland being driven by many clinical and system leaders prioritizing MBC as a foundational component of evidence based service delivery, as they recognize its importance in ensuring high-quality care.
  • This prioritization is clear in the recently announced $120 million in grant funding by the Maryland Consortium on Coordinated Community Support, which strongly encourages the implementation of MBC by providers working in school settings.
  • It is very promising to see Maryland’s Consortium working to drive improvement and innovation across their behavioral health services.”
    To learn more about implementing Measurement-Based Care to enhance the quality of your behavioral health services, please visit greenspacehealth.com .
  • For more information about Measurment-Based Care and the MDCBH coordinated implementation, please visit:

Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023

Retrieved on: 
Thursday, November 30, 2023
Oncology, Health, Consumer, Hospitals, Women, Pharmaceutical, Biotechnology, Data, Research, Senior, ADC, Patient, MBC, Breast, Caregiver, MD, Survival, Doctor of Philosophy, Quality of life, Science, TNBC, Sacituzumab govitecan

Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
  • “Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both second-line metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology.
  • “The data being presented at SABCS add to the breadth of evidence reinforcing Trodelvy's use in these two difficult-to-treat breast cancers.
  • Additionally, the real-world data being presented in metastatic breast cancer provide insights on quality of life and other measures of health to inform both providers and patients in making treatment decisions.”

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Monday, November 20, 2023
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Woman, Safety, Food, Therapy, European Commission, ASH, HIV disease progression rates, Civil service commission, Patient, Multimedia, ESR1, FDA, MBC, Menarini, Bone marrow, Cancer, Survival, Biomarker, Society, Mutation, BPDCN, Pharmaceutical industry, Dietary supplement, Medical imaging

In September 2023 , ORSERDU was approved by the European Commission.

Key Points: 
  • In September 2023 , ORSERDU was approved by the European Commission.
  • Updated data, including a spotlight discussion on additional biomarker and clinical subgroup analyses from the Phase 3 EMERALD trial, along with new safety updates evaluating elacestrant in multiple combination settings, will be presented at the San Antonio Breast Cancer Symposium (SABCS), December 5-9, 2023.
  • Updated data, including an oral presentation of updated real-world results in treatment-naïve patients with BPDCN demonstrating durable outcomes and a manageable safety profile leading to prolonged survival, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, December 9-12, 2023.
  • “The breadth of data on our novel oncology therapies, spanning solid tumors and hematologic malignancies, underscore our commitment to addressing significant unmet medical needs in difficult-to-treat cancers,” said Elcin Barker Ergun, CEO of the Menarini Group.

SimplePractice Launches a Measurement-Based Care Solution to Enhance Patient Progress Tracking

Retrieved on: 
Wednesday, November 15, 2023
Data Management, Health, Technology, Practice Management, Software, General Health, MBC, NYSE, Face, Entrepreneurship, LPC, Nursing

The new solution will enable practitioners to more easily use systematic assessments of a patient's progress to inform treatment decisions.

Key Points: 
  • The new solution will enable practitioners to more easily use systematic assessments of a patient's progress to inform treatment decisions.
  • The SimplePractice MBC solution seamlessly integrates into practitioners’ existing workflows, offering evidence-based and data-interpreting features, including:
    Visual charting: access to easy-to-read documents and visualization charts to showcase changes over time.
  • “The launch of our measurement-based care solution is a critical resource for the more than 185,000 practitioners we support," said Jonathan Seltzer, President of SimplePractice.
  • Automating measurement-based care into our existing SimplePractice client experience and intake process is so invaluable for me and my team.”

Astellas and MBC BioLabs Announce 2023 Future Innovator Prize Awarded to TippingPoint Biosciences and Altay Therapeutics

Retrieved on: 
Wednesday, December 13, 2023
Genetics, Research, SAN, Therapy, Gene, Toxicity, IND, Biotechnology, FSHD, AVM, Patient, Mission, Idiopathic pulmonary fibrosis, Doctor of Philosophy, Altai, Drug resistance, TSE, Genome, Chromatin, Factorization of polynomials, Drug discovery, Cancer, TippingPoint, MBC, San Francisco Bay Area, Facioscapulohumeral muscular dystrophy, Pharmaceutical industry, Astellas Pharma

"We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.

Key Points: 
  • "We extend our congratulations to TippingPoint Biosciences and Altay Therapeutics for their remarkable achievements in therapeutics research.
  • "It's such an honor to be a recipient of the Astellas Future Innovator Prize, which will further support TippingPoint's research," said Laura Hsieh, CEO of TippingPoint Biosciences.
  • "Astellas' deep industry expertise coupled with MBC BioLabs' resources will play integral roles in accelerating our drug discovery development and successfully implementing TippingPoint's programs.
  • Both TippingPoint Biosciences and Altay Therapeutics will reside at MBC BioLabs with the next year sponsored by Astellas.

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Retrieved on: 
Friday, December 8, 2023
Trastuzumab, Research, Progression-free survival, RECIST, Fulvestrant, Breast cancer, Jazz Pharmaceuticals, Patient, PFS, Part, Corr, DOR, MBC, DCR, Pertuzumab, HER2, Cancer, Vall d'Hebron University Hospital, BS 5839 Part 1, Metastasis, HR, Pharmaceutical industry, Medical imaging, MD

DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • DUBLIN, Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS).
  • Patients treated with the combination regimen received a median of four prior systemic regimens in the metastatic setting (range, 1-12).
  • Recommended doses of the zanidatamab plus palbociclib and fulvestrant combination therapy were determined in Part 1 of the study.
  • Patients treated with the combination regimen achieved a cORR of 35% and DCR of 91%.

Montclair Breast Center Celebrates a Trailblazer: Breast Surgeon Elissa J. Santoro, MD

Retrieved on: 
Tuesday, December 5, 2023
Woman, Highlawn, West Virginia, Breast cancer, Breast Cancer Research, Karger Publishers, Surgeon, Hospital, Patient, Research, FACS, Health, Friends, Mentorship, Breast, MD, Hand, St. Vincent's Hospital, MBC, Genesis Health System, Elective surgery, Female, Publication, Environment, Health department, Birth control, Medicine

Dr. Santoro is a distinguished and revolutionary breast surgeon whose contributions have left an indelible mark on the field of breast health.

Key Points: 
  • Dr. Santoro is a distinguished and revolutionary breast surgeon whose contributions have left an indelible mark on the field of breast health.
  • She founded the Breast Care and Treatment Center in Livingston, NJ and has appeared on several televised educational programs.
  • Her leadership at Montclair Breast Center fosters an environment of innovation where cutting-edge research and patient-centric care go hand in hand.
  • Coming full circle, Dr. Santoro joined Dr. Elliott at Montclair Breast Center in March 2022.